Bone structure and formation rates didn't change, and the authors say the signal isn't enough to show a lasting bone-building effect.
Recap by typeshit. Full story at Bioengineer.org.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Prime Hospital Rewari offers a basic explainer on tirzepatide versus insulin and says to use either only under medical supervision.
Roy writes for people on Ozempic or Wegovy worried about later effects, pointing to big trials that tallied side effects.
Loading…